|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM348316607 |
| 003 |
DE-627 |
| 005 |
20231226035904.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202206510
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1161.xml
|
| 035 |
|
|
|a (DE-627)NLM348316607
|
| 035 |
|
|
|a (NLM)36317605
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Wang, Xinzhu
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A Dual-Locked Tandem Fluorescent Probe for Imaging of Pyroptosis in Cancer Chemo-Immunotherapy
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 14.03.2023
|
| 500 |
|
|
|a Date Revised 14.03.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2023 Wiley-VCH GmbH.
|
| 520 |
|
|
|a Real-time imaging of programmed cancer cell death (PCD) is imperative to monitor cancer therapeutic efficacy and tailor therapeutic regimens; however, specific in vivo detection of intratumoral pyroptosis remains challenging. Herein, a dual-locked and tandem activatable probe (DTAP) is reported for near-infrared fluorescence (NIRF) imaging of intratumoral pyroptosis during cancer chemo-immunotherapy in living mice. The probe comprises a hemicyanine dye dual-locked with an enzyme-responsive moiety that can be tandemly cleaved by pyroptosis-related biomarker (Caspase-1) and cancer biomarker (GGT) to turn on its NIRF signal. As pyroptosis plays a vital role in triggering anti-tumor immune responses, the activated signal of DTAP correlates well with the population of tumor-infiltrating cytotoxic T lymphocytes and tumor growth inhibition, consequently permitting the prediction of cancer therapeutic efficacy. This study also provides a non-invasive technique to study the regulatory mechanism of pyroptosis in cancer therapy and to optimize cancer chemo-immunotherapies for precision medicine
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a activatable fluorescent probes
|
| 650 |
|
4 |
|a cancer chemo-immunotherapy
|
| 650 |
|
4 |
|a dual-locked probes
|
| 650 |
|
4 |
|a fluorescence Imaging
|
| 650 |
|
4 |
|a intratumoral pyroptosis
|
| 650 |
|
7 |
|a Fluorescent Dyes
|2 NLM
|
| 700 |
1 |
|
|a He, Shasha
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cheng, Penghui
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pu, Kanyi
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 35(2023), 10 vom: 23. März, Seite e2206510
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:35
|g year:2023
|g number:10
|g day:23
|g month:03
|g pages:e2206510
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202206510
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 35
|j 2023
|e 10
|b 23
|c 03
|h e2206510
|